Valuation: Alector, Inc.

Market Cap 213M 190M 177M 161M 303M 20.2B 308M 2.13B 832M 10.54B 800M 783M 33.72B P/E 2026 *
-4.23x
P/E 2027 * -2.28x
Enterprise Value -48.74M -43.51M -40.44M -36.78M -69.2M -4.62B -70.45M -486M -190M -2.41B -183M -179M -7.71B EV / Sales 2026 *
-0.74x
EV / Sales 2027 * -8.12x
Free-Float
90.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+6.28%
1 week-5.45%
Current month+3.24%
1 month-6.14%
3 months+27.33%
6 months-25.97%
Current year+22.44%
1 week 1.78
Extreme 1.775
2.14
1 month 1.73
Extreme 1.73
2.73
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.34
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 71 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Sell

Controller/Auditor

-3,625 0.0032%
9/3/26 Sell

Chief Financial Officer

-29,251 0.0262%
9/3/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
+6.28%-5.45%-40.13%-68.17% 213M
+0.21%-4.63%+55.34%+71.32% 68.98B
-2.43%+1.70%+4.16%+57.62% 53.15B
-0.53%+5.10%+9.70%+41.14% 50.83B
+0.51%+4.70%+33.44%+35.96% 44.61B
-1.31%+0.61%+281.88%+532.76% 40.57B
-0.06%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
-0.64%-2.02%-13.55%-12.92% 22.66B
Average +0.34%+0.86%+39.23%+81.04% 37.99B
Weighted average by Cap. -0.34%+2.33%+50.23%+102.60%

Financials

2026 *2027 *
Net sales 66.15M 59.05M 54.88M 49.92M 93.91M 6.27B 95.61M 659M 258M 3.27B 248M 243M 10.46B 11.4M 10.17M 9.45M 8.6M 16.18M 1.08B 16.47M 114M 44.44M 563M 42.77M 41.86M 1.8B
Net income -51.03M -45.55M -42.34M -38.51M -72.45M -4.83B -73.76M -509M -199M -2.52B -192M -187M -8.07B -111M -98.92M -91.94M -83.63M -157M -10.5B -160M -1.1B -432M -5.48B -416M -407M -17.52B
Net Debt -262M -234M -217M -198M -372M -24.82B -379M -2.61B -1.02B -12.95B -983M -962M -41.43B -306M -273M -254M -231M -434M -28.97B -442M -3.05B -1.19B -15.11B -1.15B -1.12B -48.36B
Projected Income Statement - Annual - Alector, Inc.
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-10-16 $1.985 +3.93% 2,090,007
26-10-15 $1.910 +1.60% 1,630,377
26-10-14 $1.880 +0.53% 2,912,375
26-10-13 $1.870 -10.10% 2,843,592
26-10-12 $2.080 0.00% 1,630,342
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Alector, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.910USD
Average target price
3.900USD
Spread / Average Target
+104.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alector, Inc.
  1. Stock Market
  2. Stocks
  3. ALEC Stock